23andMe Holding Co.
NASDAQ:ME

Watchlist Manager
23andMe Holding Co. Logo
23andMe Holding Co.
NASDAQ:ME
Watchlist
Price: 0.6063 USD -21.26% Market Closed
Market Cap: 88.5m USD

Operating Margin

-99.4%
Current
Improving
by 25.1%
vs 3-y average of -124.5%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-99.4%
=
Operating Income
$-207.5m
/
Revenue
$208.8m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-99.4%
=
Operating Income
$-207.5m
/
Revenue
$208.8m

Peer Comparison

Country Company Market Cap Operating
Margin
US
23andMe Holding Co.
NASDAQ:ME
88.5m USD
Loading...
US
CVS Health Corp
NYSE:CVS
101.5B USD
Loading...
US
Cigna Corp
NYSE:CI
72.6B USD
Loading...
US
Cigna Group
XMUN:CGN
62B EUR
Loading...
DE
Fresenius SE & Co KGaA
XETRA:FRE
26.6B EUR
Loading...
DE
Fresenius Medical Care AG
XMUN:FME
21.3B EUR
Loading...
US
Laboratory Corporation of America Holdings
NYSE:LH
22.8B USD
Loading...
US
Quest Diagnostics Inc
NYSE:DGX
21.2B USD
Loading...
US
Guardant Health Inc
NASDAQ:GH
14.1B USD
Loading...
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
10.5B EUR
Loading...
AU
Sonic Healthcare Ltd
ASX:SHL
11.2B AUD
Loading...
No Stocks Found

Market Distribution

Lower than 85% of companies in the United States of America
Percentile
15th
Based on 14 112 companies
15th percentile
-99.4%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

23andMe Holding Co.
Glance View

Market Cap
88.5m USD
Industry
Health Care

23andMe Holding Co. is consumer genetics and research company, which engages to help people access, understand, and benefit from the human genome. The company is headquartered in South San Francisco, California. The company went IPO on 2020-10-06. The firm offers direct-to-consumer genetic testing and personalized information about genetic health risks, ancestry, and traits. The firm operates through two segments: Consumer & Research Services and Therapeutics. Its consumer & research services business segment comprises personal genome service (PGS) and research services. Its PGS provides a suite of genetic reports, including information on genetic ancestral origins, personal genetic health risks, rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Company’s therapeutics segment focuses on drug development for discovering and developing therapies to improve patient lives and includes out-licensing of intellectual property. The Company’s programs across therapeutic areas, include oncology, immunology, neurology, metabolic and cardiovascular diseases.

ME Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-99.4%
=
Operating Income
$-207.5m
/
Revenue
$208.8m
What is 23andMe Holding Co.'s current Operating Margin?

The current Operating Margin for 23andMe Holding Co. is -99.4%, which is above its 3-year median of -124.5%.

How has Operating Margin changed over time?

Over the last 3 years, 23andMe Holding Co.’s Operating Margin has decreased from -96.9% to -99.4%. During this period, it reached a low of -145.2% on Mar 31, 2024 and a high of -93.5% on Mar 31, 2022.

Back to Top